- PIPELINE
- INVESTORS
- CONTACT US
Research Status
PIPELINE
Research Status
With TOFPOMICS®, a technology development platform, ONCOBIX has a range of drug discovery pipelines for the 4th-generation NSCLC therapies, pulmonary fibrosis therapies, and pancreatic/lung cancer therapies, and we are further expanding our pipelines through continuous dedication to research.
- Objectives Per Task : Identify and discover new best-in-kinase drugs
| Pipeline | Indication | Platform | Discovery | Development | ||||
|---|---|---|---|---|---|---|---|---|
| Hit/lead compound | Candidate compound | Preclinical | Phase I | Phase II | Phase III | |||
| In House Research | ||||||||
| OBX02 Series | EGFR: Non-Small Cell Lung Cancer |
|||||||
Idiopathic/radiotherapy-induced pulmonary fibrosis |
||||||||
| OBX10 Series | EGFR mediated EMT: |
|||||||
| OBX13 Series | ALK/ROS1: Non-Small Cell Lung Cancer |
|||||||
| OBX09 Series | FAK: Lung cancer/pancreatic cancer |
|||||||
| Joint Research | ||||||||
| OBX08 Series | Non-Small Cell Lung Cancer |
TOFPOMICS® |
||||||
| OBX16 Series | Immuno-oncology |
|||||||
| OBX17 Series | Psoriasis |
|||||||
EGFR, epidermal growth factor receptor; EMT, epithelial-mesenchymal transition; ALK, Anaplastic lymphoma kinase; ROS1, c-ros oncogene 1; FAK, focal adhesion kinase
Development Stage: Hit (Hit compound) => Lead (Lead compound) => Candidate (Candidate compound)